Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Cancer Immunology, Immunotherapy
Published in: Cancer Immunology, Immunotherapy 5/2014

01-05-2014 | Meeting Report

Second Ascoli Piceno conference on gene vaccination in cancer (GVC), Ascoli Piceno, Italy, October 9–11, 2013

Authors: Elisabetta Bolli, Laura Conti, Federica Riccardo, Cristina Marchini, Augusto Amici, Federica Cavallo, Elena Quaglino

Published in: Cancer Immunology, Immunotherapy | Issue 5/2014

Login to get access

Excerpt

The gene vaccination in cancer (GVC) meeting offered the opportunity to continue and strengthen the existing national and international collaborations between basic scientists, clinical researchers and scientists in industry to overcome obstacles in gene vaccination against cancer. The 2013 GVC meeting covered the following topics: (1) new technologies for gene vaccination; (2) emerging targets for cancer vaccines; (3) therapeutic vaccination against human papillomavirus (HPV)-dependent diseases; (4) preclinical challenges; (5) veterinary applications of gene vaccination in cancer; (6) in vivo gene-electro-transfer: from technology development to clinical applications. …
Metadata
Title
Second Ascoli Piceno conference on gene vaccination in cancer (GVC), Ascoli Piceno, Italy, October 9–11, 2013
Authors
Elisabetta Bolli
Laura Conti
Federica Riccardo
Cristina Marchini
Augusto Amici
Federica Cavallo
Elena Quaglino
Publication date
01-05-2014
Publisher
Springer Berlin Heidelberg
Published in
Cancer Immunology, Immunotherapy / Issue 5/2014
Print ISSN: 0340-7004
Electronic ISSN: 1432-0851
DOI
https://doi.org/10.1007/s00262-014-1526-y

Other articles of this Issue 5/2014

Cancer Immunology, Immunotherapy 5/2014 Go to the issue

Original Article

Alterations of costimulatory molecules and instructive cytokines expressed by dendritic cells in the microenvironment of an endogenous mouse lymphoma

Original Article

Tumor-induced STAT3 activation in monocytic myeloid-derived suppressor cells enhances stemness and mesenchymal properties in human pancreatic cancer

Original Article

Induction of tumor-reactive T helper responses by a posttranslational modified epitope from tumor protein p53

Original Article

ImmTAC-redirected tumour cell killing induces and potentiates antigen cross-presentation by dendritic cells

Original Article

Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanoma

Original Article

Recombinant IL-21 and anti-CD4 antibodies cooperate in syngeneic neuroblastoma immunotherapy and mediate long-lasting immunity
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits